secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001558370-22-011546
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q2 total revenues up 29% to $911M; raises Jakafi guidance bottom end
---------------------------------------------------------------------------

- Total revenues $911M (+29% YoY); product revenues $664M (+15% YoY).
- Jakafi net product revenues $598M (+13% YoY); FY guidance raised to $2.36-$2.40B.
- GAAP diluted EPS $0.72; Non-GAAP diluted EPS $1.01 (up from $0.80 YoY).
- Opzelura approved for vitiligo in July; ~48,000 units shipped in Q2 in atopic dermatitis launch.
- Itacitinib development in chronic GVHD halted; pivotal trial deemed unlikely to succeed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000155837022011546/0001558370-22-011546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000155837022011546/incy-20220802x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-011546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer